Pancreatic cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Pancreatic cancer pathologically proven with pancreatic juice or biops. 2) Clinical stage IIA, IIB, III (UICC) 3) ECOG PS;0-1 4) Without previous surgical resection for pancreatic cancer or irradiation to upper abdomen 5) adequate oral intake 6) Adequate organ functions; white blood cells >= 3,000/m3 Neutrophil>=2000/m3 platelets >= 100,000/m3 hemoglobin >= 9.0g/dl AST<= 150 U/L ALT<= 150 U/L total bilirubin <= 2.0mg/dL Creatinine <= 1.2mg/dL Albumin >= 3.0 mg/dL Without fever over 38 degree 7) diagnosed as capable of dynamic tumor tracking with inserted fiducial marker 8) Written Informed Consent
Exclusion criteria
Exclusion criteria: 1) Intersitial pneumonia or pulmonary fibrosis 2) previous irradiation to upper abdomen 3) Severe comorbidity 4) Pleural effusion or Ascites 5) Tumor invasion to stomach, duodenum or intestine 6) Patients with double cancer (double cancer or treated cancer with no more than 3-year disease-free period). However, carcinoma in situ or intra-mucosal cancer-equivalent lesion are not to be included in double cancer 7) Severe allergy history to gold 8) Unstable and Uncontrollable diabetic mellitus, or severe collagen disease 9) Woman during pregnancy or breast-feeding, patient who wish pregnancy 10) Psychiatric disease 11) Inappropriate patients for this study judged by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year freedom from loco-regional progression | — |
Secondary
| Measure | Time frame |
|---|---|
| Loco-regional progression-free survival, overall survival, progression-free survival, the incidence of acute adverse events, the incidence of late adverse events, treatment-related morbidity/early mortality , the accuracy in dynamic tumor tracking technique | — |
Countries
Japan
Contacts
Kyoto University Hospital Department of Radiation Oncology and Image-Applied Therapy